Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

Environmental factors, obesity and diabetes: Long-term study launched

Three Singapore biomedical institutions have launched a major, long-term study of pregnant mothers and their fetuses as well as infant children to determine just how profoundly environmental factors early in life influence the onset of diseases such as obesity and diabetes in later years.

10 Nov 2009

Compugen discovers new biomarker for predisposition to type 2 diabetes using its GeneVa platform

Compugen Ltd. announced today the discovery and experimental confirmation of a genetic biomarker, CGEN-40001 for predisposition to type 2 diabetes, the most common form of diabetes.

9 Nov 2009

Public health experts urge Congress not to overlook the needs of Americans with "morbid obesity"

As the House of Representatives and the Senate debate companion bills to make health care more affordable and accessible, a coalition of obesity and public health experts today urged Congress not to overlook the needs of the more than 15 million Americans who suffer from severe obesity and are at the greatest risk for chronic disease and death.

9 Nov 2009

Tethys Bioscience completes $25 million Series D financing

Tethys Bioscience, a privately held company, announced today that it has closed a $25 million Series D round of financing led by aeris CAPITAL AG and including Wasatch Advisors as a new investor. All current investors, including MDV-Mohr Davidow Ventures, Kleiner Perkins Caulfield & Byers and Intel Capital participated in the round. Tethys also announced that it has appointed George Rehm, Managing Partner of aeris CAPITAL, to the Tethys Board of Directors.

9 Nov 2009

CPEX Pharmaceuticals to feature Nasulin at the Diabetes Technology Meeting

CPEX Pharmaceuticals, Inc. today announced that its intranasal insulin product candidate, NasulinTM, will be featured in an oral presentation and four abstracts at the Ninth Annual Diabetes Technology Meeting, November 5-7, 2009 at the Hyatt Regency Airport in San Francisco, California.

6 Nov 2009

Echo Therapeutics commences its Symphony Transdermal Continuous Glucose Monitoring System clinical study

Echo Therapeutics, Inc., a diabetes management company developing the needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery announced today that it has initiated a clinical study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System (tCGM System) in patients with Type 1 and Type 2 diabetes.

5 Nov 2009

Osiris Therapeutics reports financial results for the third quarter of 2009

Osiris Therapeutics, Inc., the leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, cardiovascular and orthopedic areas, announced today its financial results for the third quarter of 2009.

4 Nov 2009

CPEX Pharmaceuticals announces third-quarter results; reports net loss of $872,000

CPEX Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2009. For the quarter CPEX reported revenues of $5.0 million and a net loss of $872,000.

4 Nov 2009

Researchers use fruit fly model for diabetes research

As rates of obesity, diabetes, and related disorders have reached epidemic proportions in the US in recent years, scientists are working from many angles to pinpoint the causes and contributing factors involved in this public health crisis. While sedentary lifestyles and diets high in sugar and fat contribute significantly to the rise in diabetes rates, genetic factors may make some people more vulnerable than others to developing diabetes.

4 Nov 2009

Breastfeeding: ADA position paper details health benefits for both infants and mothers

The American Dietetic Association has released an updated position paper on breastfeeding that details health benefits for both infants and mothers and encourages promotion of breastfeeding whenever possible.

4 Nov 2009

The Children’s Hospital leads the charge against childhood obesity

The Children’s Hospital is leading the charge against childhood obesity, a problem that is impacting more and more families across the country. Experts from The Children’s Hospital offer a pediatric perspective on proactive steps parents can take to ensure their children maintain nutritious diets and healthy, active lifestyles.

4 Nov 2009

PCNA launches "Family at Heart" educational campaign

Recent research indicates that despite decades of progress, fewer Americans are now considered "low risk" for heart disease compared to years past. Adding fuel to the fire, a new study is making headlines with the alarming statistic that 7 in 10 obese teens already have at least one risk factor for heart disease.

3 Nov 2009

Lifestyle changes prevents type 2 diabetes in people at high risk for developing the disease: Study

Sustaining modest weight loss for 10 years, or taking an anti-diabetic drug over that time, can prevent or lower the incidence of type 2 diabetes in people at high risk for developing the disease, according to the Diabetes Prevention Program Outcomes Study (DPPOS), a long-term follow-up to a landmark 2001 diabetes prevention study.

3 Nov 2009

FDA update on BYETTA injection: Amylin Pharmaceuticals and Eli Lilly respond

Amylin Pharmaceuticals, Inc., and Eli Lilly and Company today issued the following statement in response to the U.S. Food and Drug Administration (FDA) update on BYETTA® (exenatide) injection.

3 Nov 2009

FDA updates Byetta prescribing information following reports of kidney problems

The U.S. Food and Drug Administration today acted on new safety information about possible kidney function problems, including kidney failure, in patients taking Byetta (exenatide), a drug used to treat Type 2 diabetes.

3 Nov 2009

Pico-Tesla commences pilot study of its Resonator system for treating type 2 diabetes patients

Pico-Tesla, The Magneceutical™ Therapy Company, announced today that it has commenced a randomized, double-blind, placebo-controlled Pilot Study of up to 165 persons who have type 2 diabetes, the most common form of diabetes.

2 Nov 2009

American Diabetes Association launches "Stop Diabetes" campaign

Americans earn a failing grade on diabetes awareness, based on survey results released today by the American Diabetes Association. In general, Americans earned a 51% when asked a series of questions about a disease so common that it strikes every 20 seconds. The survey results revealed that many diabetes myths and misconceptions still exist, while the disease's prevalence continues to rise.

2 Nov 2009

Amylin and Takeda to develop and commercialize pharmaceutical products for obesity

Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Takeda Pharmaceutical Company Limited (TSE: 4502) announced today that they have entered into a worldwide exclusive license, development and commercialization agreement to co-develop and commercialize pharmaceutical products for the treatment of obesity and related indications.

2 Nov 2009

Amgen publishes Phase 3 study results of Aranesp

Amgen today announced the publication of results from TREAT (the Trial to Reduce Cardiovascular Events with Aranesp® Therapy), a large, randomized, double-blind, placebo-controlled, Phase 3 pivotal study of patients with chronic kidney disease (CKD) not on dialysis, moderate anemia and type-2 diabetes.

31 Oct 2009

FDA approves an expanded indication for BYETTA injection

Amylin Pharmaceuticals, Inc., and Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for BYETTA® (exenatide) injection. BYETTA is now approved for use as a stand-alone medication (monotherapy) along with diet and exercise to improve glycemic control in adults with type 2 diabetes.

31 Oct 2009

Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

Environmental factors, obesity and diabetes: Long-term study launched

Compugen discovers new biomarker for predisposition to type 2 diabetes using its GeneVa platform

Public health experts urge Congress not to overlook the needs of Americans with "morbid obesity"

Tethys Bioscience completes $25 million Series D financing

CPEX Pharmaceuticals to feature Nasulin at the Diabetes Technology Meeting

Echo Therapeutics commences its Symphony Transdermal Continuous Glucose Monitoring System clinical study

Osiris Therapeutics reports financial results for the third quarter of 2009

CPEX Pharmaceuticals announces third-quarter results; reports net loss of $872,000

Researchers use fruit fly model for diabetes research

Breastfeeding: ADA position paper details health benefits for both infants and mothers

The Children’s Hospital leads the charge against childhood obesity

PCNA launches "Family at Heart" educational campaign

Lifestyle changes prevents type 2 diabetes in people at high risk for developing the disease: Study

FDA update on BYETTA injection: Amylin Pharmaceuticals and Eli Lilly respond

FDA updates Byetta prescribing information following reports of kidney problems

Pico-Tesla commences pilot study of its Resonator system for treating type 2 diabetes patients

American Diabetes Association launches "Stop Diabetes" campaign

Amylin and Takeda to develop and commercialize pharmaceutical products for obesity

Amgen publishes Phase 3 study results of Aranesp

FDA approves an expanded indication for BYETTA injection

E-Cigarettes and Ethanol: A forensic Perspective on Vaping

Understanding Consumer-Consented Data to Optimize Digital Health Programs

The Future is Wearable: Advancing Human Health Through Portable Spectroscopy

Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

E-Cigarettes and Ethanol: A forensic Perspective on Vaping

Understanding Consumer-Consented Data to Optimize Digital Health Programs

The Future is Wearable: Advancing Human Health Through Portable Spectroscopy

Newsletters you may be interested in